Amgen Inc. Debt Instrument, Face Amount
Amgen Inc. (AMGN) had Debt Instrument, Face Amount of $4.00 billion as of 2026-03-31, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Debt
us-gaap:DebtInstrumentFaceAmount · last filed 2026-08-05
- 2026-03-31: Debt Instrument, Face Amount $4.00B.
- 2023-09-30: Debt Instrument, Face Amount $24.00B.
- 2023-06-30: Debt Instrument, Face Amount $24.00B.
- 2023-03-31: Debt Instrument, Face Amount $24.00B.
| Period end | Debt Instrument, Face Amount |
|---|---|
| 2026-03-31 | $4.00B 10-Q · filed 2026-08-05 |
| 2023-09-30 | $24.00B 10-Q · filed 2023-10-31 |
| 2023-06-30 | $24.00B 10-Q · filed 2023-08-04 |
| 2023-03-31 | $24.00B 10-Q · filed 2023-04-28 |
| 2017-12-31 | $4.50B 10-K · filed 2018-02-13 |
| 2017-05-31 | $3.50B 10-Q · filed 2017-10-26 |
| 2016-12-31 | $6.70B 10-K · filed 2018-02-13 |
| 2015-12-31 | $3.50B 10-K · filed 2018-02-13 |
| 2015-05-31 | $3.50B 8-K · filed 2016-10-31 |
| 2014-12-31 | $4.50B 10-K · filed 2017-02-14 |
| 2014-05-31 | $4.50B 10-Q · filed 2014-10-29 |
| 2013-12-31 | $8.10B 8-K · filed 2016-10-31 |
| 2012-12-31 | $5.00B 10-K · filed 2015-02-19 |
| 2012-09-30 | $2.00B 10-Q · filed 2012-11-06 |
| 2012-06-30 | $3.00B 10-Q · filed 2012-08-08 |
| 2012-05-31 | $3.00B 10-Q · filed 2012-11-06 |
| 2011-12-31 | $10.50B 10-K · filed 2014-02-24 |
| 2010-12-31 | $2.50B 10-K · filed 2013-02-27 |
| 2009-12-31 | $2.00B 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |